Nuwaysir has stepped down from his position as CEO of BlueRock and moved to in vivo cell therapy firm Ensoma.

Millie Nelson, Editor

October 13, 2021

3 Min Read
Ins and outs: High level changes at BlueRock, Pfizer and the NIH
Emile Nuwaysir, CEO at Ensome. Image c/o Ensoma

Emile Nuwaysir has stepped down from his position as CEO of BlueRock and moves to in vivo cell therapy firm Ensoma. Meanwhile, there are changes at Pfizer and the National Institutes of Health (NIH).

Nuwaysir has been CEO of Bayer’s subsidiary BlueRock Therapeutics since 2017. Since then, the company has transitioned from a preclinical start-up to a clinical-stage firm that employs over 200 people across two countries.

Nuwaysir will remain at the company as a board chair and continue to actively support BlueRock’s growth provide guidance on both R&D and corporate strategy.


Emile Nuwaysir, CEO at Ensome. Image c/o Ensoma

In his new venture, Nuwaysir has joined gene therapy firm Ensoma as CEO, president, and member of the firm’s board of directors. He aims to lead the team and advance its platform and strategic focus across multiple therapeutic areas.

BlueRock’s chief scientific officer Seth Ettenberg has assumed the role of president and CEO.

Ettenberg joined the firm in 2020 and according to BlueRock he has been an “exceptional leader” and helped shaped its pipeline and proprietary cell and gene platform.

“Emile’s leadership has been a key driving force in BlueRock’s growth. We are very grateful for his contributions and pleased that he will continue to work closely with us in his new role as board chair,” said Stefan Oelrich, member of the board of management at Bayer and president of its pharmaceuticals division.


In other news, Pfizer’s chief development officer and executive vice president Rod Mackenzie will retire from his role early next year.

Pfizer’s CEO Albert Bourla described MacKenzie’s planned departure as “bittersweet” in a statement he published on LinkedIn.

“After 35 years of outstanding service to Pfizer, my friend and colleague, Rod Mackenzie […] intends to retire early next year. Rod has been a part of so many incredible moments and milestones at Pfizer, and most importantly, his mission and drive of putting patients first has never wavered,” said Bourla.

Pfizer has named Aamir Malik as executive vice president. Malik joins the firm after 24 years as a senior partner at a management consulting company.


Francis Collins, director of the NIH, has announced he will end his tenure by the end of this year after serving three US presidents spanning over more than 12 years.

“It has been an incredible privilege to lead this great agency for more than a decade,” said Collins.

“I love this agency and its people so deeply that the decision to step down was a difficult one, done in close counsel with my wife, Diane Baker, and my family. I am proud of all we’ve accomplished. I fundamentally believe, however, that no single person should serve in the position too long, and that it’s time to bring in a new scientist to lead the NIH into the future.”

It has not been disclosed who will succeed Collins.

Thank you for joining us for this week’s Ins & Outs. If you have a story you think would work for us, please contact [email protected].

About the Author(s)

Millie Nelson

Editor, BioProcess Insider

Journalist covering global biopharmaceutical manufacturing and processing news and host of the Voices of Biotech podcast.

I am currently living and working in London but I grew up in Lincolnshire (UK) and studied in Newcastle (UK).

Got a story? Feel free to email me at [email protected]

You May Also Like